A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation

Sponsor
AbbVie
Study ID
NCT03873857
Status
Completed

Conditions

  • Cancer
  • Chronic Lymphocytic Leukemia (CLL)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study seeks to assess the effectiveness and safety of venetoclax in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) in a real-world setting across clinical practice in the Russian Federation.

Key Dates

Start date
Feb 25, 2019
Status verified
Aug 2023
Primary completion
Sep 12, 2022
Completion
Sep 12, 2022

Study Design

Enrollment
71 participants (actual)

Arms

  • Arm: Venetoclax
    Participants in this observational study will receive treatment with venetoclax for up to 24 months for treatment of relapsed or refractory CLL. The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study.

Primary Outcome Measure

Objective Response Rate (ORR) 12 Months after Treatment Initiation [ Time Frame: Up to approximately 12 months after treatment initiation ]

Related Studies